How The FDA Has Been Able To Adjust To Accelerate COVID-19 Therapeutic Development
Source: Life Science Leader
Rob Wright, chief editor of Life Science Leader, conducted a virtual roundtable with four CEOs and company founders (view full video here). In this clip, Jonathan Javitt, M.D., CEO of Neuro Rx, and Mei Mei Hu, cofounder and co-CEO of COVAXX, reflect on how the FDA has adjusted to accommodate accelerated timelines for development of COVID-19 therapeutics.
This website uses cookies to ensure you get the best experience on our website. Learn more